



Clinical trial results:

Phase 1/2 Study of Intratumoral G100 with or without Pembrolizumab or Rituximab in Patients with Follicular Non-Hodgkin's Lymphoma

Summary

EudraCT number	2015-005382-23
Trial protocol	GB ES FR
Global end of trial date	01 August 2019

Results information

Result version number	v1 (current)
This version publication date	12 August 2020
First version publication date	12 August 2020

Trial information

Trial identification

Sponsor protocol code	MK-3475-174 (IMDZ-G142)
-----------------------	-------------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02501473
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 August 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 August 2019
Global end of trial reached?	Yes
Global end of trial date	01 August 2019
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

This is a Phase 1/2 open label trial of G100 in participants with low grade Non-Hodgkin's Lymphoma (NHL). G100 is composed of glucopranosyl lipid A in a stable emulsion and is a potent TLR4 (toll-like receptor-4) agonist. G100 will be administered by direct injection (intratumorally) into tumors of low grade NHL with or without standard low dose radiation therapy. Preclinical models and clinical studies in other cancers such as Merkel cell carcinoma have demonstrated that G100 administered in this manner can alter the tumor microenvironment, activate dendritic cells, T cells and other immune cells and induce systemic anti-tumor immune responses. In this trial, the safety, immunogenicity, and preliminary clinical efficacy of G100 will be examined alone or with pembrolizumab.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 February 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	16 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 41
Country: Number of subjects enrolled	United Kingdom: 2
Country: Number of subjects enrolled	France: 1
Country: Number of subjects enrolled	Spain: 8
Worldwide total number of subjects	52
EEA total number of subjects	11

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	31
From 65 to 84 years	21
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled in the study at clinical sites in the United States and Europe.

Pre-assignment

Screening details:

Part 5, G100 plus Rituximab, Dose Escalation: 12 to 24 participants were planned; no participant was enrolled or dosed.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part 1: Local Radiation + G100 5µg/lesion

Arm description:

Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.

Arm type	Experimental
Investigational medicinal product name	G100
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intratumoral use

Dosage and administration details:

G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.

Investigational medicinal product name	Local radiation
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Radionuclide generator
Routes of administration	Local use

Dosage and administration details:

Radiation of a tumor in the radiation field on Day 1.

Arm title	Part 1: Local Radiation + G100 10µg/lesion
------------------	--

Arm description:

Part 1: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.

Arm type	Experimental
Investigational medicinal product name	Local radiation
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Radionuclide generator
Routes of administration	Local use

Dosage and administration details:

Radiation of a tumor in the radiation field on Day 1.

Investigational medicinal product name	G100
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intratumoral use
Dosage and administration details:	
G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Arm title	Part 2: Local Radiation + G100 10µg/lesion
Arm description:	
Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Arm type	Experimental
Investigational medicinal product name	Local radiation
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Radionuclide generator
Routes of administration	Local use
Dosage and administration details:	
Radiation of a tumor in the radiation field on Day 1.	
Investigational medicinal product name	G100
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intratumoral use
Dosage and administration details:	
G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Arm title	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Arm description:	
Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.	
Arm type	Experimental
Investigational medicinal product name	G100
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intratumoral use
Dosage and administration details:	
G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.	
Investigational medicinal product name	Local radiation
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Radionuclide generator
Routes of administration	Local use

Dosage and administration details:

Radiation of a tumor in the radiation field on Day 1.

Arm title	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors
Arm description: Part 2: Local radiation and G100 at 20µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks.	
Arm type	Experimental
Investigational medicinal product name	Local radiation
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Radionuclide generator
Routes of administration	Local use
Dosage and administration details: Radiation of a tumor in the radiation field on Day 1.	
Investigational medicinal product name	G100
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intratumoral use
Dosage and administration details: G100 at 20 µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks.	
Arm title	Part 3: Local Radiation + G100 20µg/lesion
Arm description: Part 3: Local radiation and G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Arm type	Experimental
Investigational medicinal product name	G100
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intratumoral use
Dosage and administration details: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Investigational medicinal product name	Local radiation
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Radionuclide generator
Routes of administration	Local use
Dosage and administration details: Radiation of a tumor in the radiation field on Day 1.	
Arm title	Part 4: G100 20µg/lesion and Pembrolizumab 200mg
Arm description: Part 4: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks and Pembrolizumab 200mg IV and administered Q3W for up to 2 years.	
Arm type	Experimental

Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.	
Investigational medicinal product name	G100
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intratumoral use
Dosage and administration details:	
G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.	

Number of subjects in period 1	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion
Started	3	3	13
Treated	3	3	13
Completed	0	0	0
Not completed	3	3	13
Adverse event, serious fatal	-	-	1
Consent withdrawn by subject	-	-	3
Study Terminated	2	3	7
Lost to follow-up	1	-	1
Reason not specified	-	-	1

Number of subjects in period 1	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion
Started	14	4	14
Treated	13	4	14
Completed	0	0	0
Not completed	14	4	14
Adverse event, serious fatal	1	-	1
Consent withdrawn by subject	3	2	2
Study Terminated	9	2	10
Lost to follow-up	-	-	1
Reason not specified	1	-	-

Number of subjects in period 1	Part 4: G100 20µg/lesion and Pembrolizumab 200mg
Started	1

Treated	1
Completed	0
Not completed	1
Adverse event, serious fatal	-
Consent withdrawn by subject	-
Study Terminated	1
Lost to follow-up	-
Reason not specified	-

Baseline characteristics

Reporting groups

Reporting group title	Part 1: Local Radiation + G100 5µg/lesion
Reporting group description: Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.	
Reporting group title	Part 1: Local Radiation + G100 10µg/lesion
Reporting group description: Part 1: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Reporting group title	Part 2: Local Radiation + G100 10µg/lesion
Reporting group description: Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Reporting group title	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Reporting group description: Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.	
Reporting group title	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors
Reporting group description: Part 2: Local radiation and G100 at 20µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks.	
Reporting group title	Part 3: Local Radiation + G100 20µg/lesion
Reporting group description: Part 3: Local radiation and G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Reporting group title	Part 4: G100 20µg/lesion and Pembrolizumab 200mg
Reporting group description: Part 4: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks and Pembrolizumab 200mg IV and administered Q3W for up to 2 years.	

Reporting group values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion
Number of subjects	3	3	13
Age categorical			
There was no enrollment in Part 5.			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	2	6
From 65-84 years	1	1	7
85 years and over	0	0	0

Age Continuous			
Age not reported for the participant in Part 4 due to risk of identification of a person. No participants were enrolled in Part 5.			
Units: years			
arithmetic mean	54.0	56.3	60.2
standard deviation	± 13.45	± 16.07	± 10.26
Sex: Female, Male			
No participants enrolled in Part 5.			
Units: Participants			
Female	1	2	3
Male	2	1	10
Race (NIH/OMB)			
No participants enrolled in Part 5.			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	1
White	2	3	11
More than one race	0	0	0
Unknown or Not Reported	1	0	1
Ethnicity (NIH/OMB)			
No participants enrolled in Part 5.			
Units: Subjects			
Hispanic or Latino	0	1	1
Not Hispanic or Latino	2	2	12
Unknown or Not Reported	1	0	0

Reporting group values	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion
Number of subjects	14	4	14
Age categorical			
There was no enrollment in Part 5.			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	10	3	8
From 65-84 years	4	1	6
85 years and over	0	0	0
Age Continuous			
Age not reported for the participant in Part 4 due to risk of identification of a person. No participants were enrolled in Part 5.			
Units: years			
arithmetic mean	57.6	59.3	63.9
standard deviation	± 10.98	± 5.85	± 8.74

Sex: Female, Male			
No participants enrolled in Part 5.			
Units: Participants			
Female	3	1	5
Male	11	3	9
Race (NIH/OMB)			
No participants enrolled in Part 5.			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	1
White	13	2	12
More than one race	0	0	0
Unknown or Not Reported	1	1	1
Ethnicity (NIH/OMB)			
No participants enrolled in Part 5.			
Units: Subjects			
Hispanic or Latino	3	0	0
Not Hispanic or Latino	11	4	13
Unknown or Not Reported	0	0	1

Reporting group values	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	Total	
Number of subjects	1	52	
Age categorical			
There was no enrollment in Part 5.			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	31	
From 65-84 years	1	21	
85 years and over	0	0	
Age Continuous			
Age not reported for the participant in Part 4 due to risk of identification of a person. No participants were enrolled in Part 5.			
Units: years			
arithmetic mean	0		
standard deviation	± 0	-	
Sex: Female, Male			
No participants enrolled in Part 5.			
Units: Participants			
Female	1	16	
Male	0	36	

Race (NIH/OMB)			
No participants enrolled in Part 5.			
Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	0	1	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	0	2	
White	1	44	
More than one race	0	0	
Unknown or Not Reported	0	5	
Ethnicity (NIH/OMB)			
No participants enrolled in Part 5.			
Units: Subjects			
Hispanic or Latino	0	5	
Not Hispanic or Latino	1	45	
Unknown or Not Reported	0	2	

End points

End points reporting groups

Reporting group title	Part 1: Local Radiation + G100 5µg/lesion
Reporting group description: Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.	
Reporting group title	Part 1: Local Radiation + G100 10µg/lesion
Reporting group description: Part 1: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Reporting group title	Part 2: Local Radiation + G100 10µg/lesion
Reporting group description: Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Reporting group title	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Reporting group description: Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.	
Reporting group title	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors
Reporting group description: Part 2: Local radiation and G100 at 20µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks.	
Reporting group title	Part 3: Local Radiation + G100 20µg/lesion
Reporting group description: Part 3: Local radiation and G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.	
Reporting group title	Part 4: G100 20µg/lesion and Pembrolizumab 200mg
Reporting group description: Part 4: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks and Pembrolizumab 200mg IV and administered Q3W for up to 2 years.	

Primary: Number of Participants with an Adverse Event (AE)

End point title	Number of Participants with an Adverse Event (AE) ^[1]
End point description: An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The analysis population included all enrolled participants who received at least 1 injection of G100 after standard local radiation.	
End point type	Primary
End point timeframe: Up to approximately 42 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	13	13
Units: Participants	3	3	13	13

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	14	1	
Units: Participants	4	14	1	

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

End point title	Number of Participants Who Discontinued Study Drug Due to an Adverse Event ^[2]
-----------------	---

End point description:

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The analysis population included all enrolled participants who received at least 1 injection of G100 after standard local radiation.

End point type	Primary
----------------	---------

End point timeframe:

Up to approximately 105 weeks

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	13	13
Units: Participants	0	0	0	2

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	14	1	
Units: Participants	0	1	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORR) by Immune-related Response Criteria (irRC)

End point title	Overall Response Rate (ORR) by Immune-related Response Criteria (irRC)
-----------------	--

End point description:

Overall response rate was defined as participants with best overall response of immune-related complete response (irCR) or immune-related partial response (irPR). irRC requires confirmatory restaging to determine if tumor size increase is due to true progression instead of immune inflammation and that new lesions add to tumor size calculations are not determinants of progressive disease by themselves. An irCR is the disappearance of all lesions, and no new lesions; an irPR is a $\geq 50\%$ drop in tumour burden from baseline; and immune related Progressive Disease (irPD) is a $\geq 25\%$ increase in tumour burden from the lowest level recorded. Everything else is considered immune-related Stable Disease (irSD). Tumor staging using bi-dimensional measurements was performed by CT or MRI. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post baseline disease assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 42 months

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	13	13
Units: Participants				
Complete Response (irCR)	0	0	0	0
Partial Response (irPR)	1	2	3	6
Stable Disease (irSD)	2	1	8	6
Progressive Disease (irPD)	0	0	2	1

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	14	1	
Units: Participants				
Complete Response (irCR)	0	0	0	
Partial Response (irPR)	1	6	0	
Stable Disease (irSD)	3	7	1	
Progressive Disease (irPD)	0	1	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical Benefit Rate (CBR) Using Immune-related Response Criteria (irRC)

End point title	Clinical Benefit Rate (CBR) Using Immune-related Response Criteria (irRC)
-----------------	---

End point description:

Clinical benefit rate (CBR) was defined as the number and percent of participants with best overall response of Immune related Response Criteria (irRC); complete response, partial response or stable disease (irCR+irPR+irSD). irRC requires confirmatory restaging to determine if tumor size increase is due to true progression instead of immune inflammation and that new lesions add to tumor size calculations and are not determinants of progressive disease by themselves. irCR is the disappearance of all lesions, and no new lesions; irPR is a $\geq 50\%$ drop in tumor burden from baseline; and immune-related Progressive Disease (irPD) is a $\geq 25\%$ increase in tumor burden from the lowest level recorded. Everything else is considered irSD. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 42 months

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	13	13
Units: Percent of participants				
number (confidence interval 95%)	100 (29.2 to 100)	100 (29.2 to 100)	84.6 (54.6 to 98.1)	92.3 (64.0 to 99.8)

End point values	Part 2: Local Radiation,	Part 3: Local Radiation +	Part 4: G100 20µg/lesion	
------------------	--------------------------	---------------------------	--------------------------	--

	G100 20µg/lesion in Large Tumors	G100 20µg/lesion	and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	14	1	
Units: Percent of participants				
number (confidence interval 95%)	100 (39.8 to 100)	92.9 (66.1 to 99.8)	100 (2.5 to 100)	

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical Benefit Rate (CBR) Using International Working Group (IWG) Criteria

End point title	Clinical Benefit Rate (CBR) Using International Working Group (IWG) Criteria
End point description:	
Clinical benefit rate (CBR) was all participants with best overall response of complete response, partial response or stable disease (CR+PR+SD). The IWG criteria (Cheson et al 2014) for a CR is a complete radiologic response (target nodes/nodal masses must regress to ≤ 1.5 cm in longest transverse diameter (LDi), no extralymphatic sites of disease, and no new tumors. A PR is a $\geq 50\%$ decrease in SPD (sum of the product of the perpendicular diameters for multiple tumors) of up to 6 target measurable nodes and extranodal sites, spleen must have regressed by $> 50\%$ in length beyond normal, and no new tumors. Stable disease is a $< 50\%$ decrease from baseline in SPD of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met, and no new tumors. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.	
End point type	Secondary
End point timeframe:	
Up to approximately 42 months	

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	13	13
Units: Percentage of participants				
number (confidence interval 95%)	100 (29.2 to 100)	100 (29.2 to 100)	84.6 (54.6 to 98.1)	92.3 (64.0 to 99.8)

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
------------------	---	---	--	--

Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	14	1	
Units: Percentage of participants				
number (confidence interval 95%)	100 (39.8 to 100)	78.6 (49.2 to 95.3)	100 (2.5 to 100)	

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR) by Immune-related Response Criteria (irRC)

End point title	Duration of Response (DOR) by Immune-related Response Criteria (irRC)
End point description:	
Duration of response (DOR) was defined as the time interval between the date of the earliest qualifying confirmed/unconfirmed response using irRC and the date of disease progression (PD) or death for any cause, whichever occurs first. DOR in months was calculated as: (date of PD or death minus date of first confirmed/unconfirmed irCR/CR or irPR/PR + 1)/30.4375. DOR analysis included only participants with confirmed/unconfirmed response of irCR/irPR using irRC. Immune-related Progressive Disease (irPD) is a $\geq 25\%$ increase in tumor burden from the lowest level recorded. Median DOR with the corresponding two-sided 95% CI was estimated using the Kaplan-Meier method in each treatment group. The analysis population included all enrolled participants who received at least 1 injection of G100 after standard local radiation and had a confirmed/unconfirmed response of irCR/irPR using irRC.	
End point type	Secondary
End point timeframe:	
Up to approximately 42 months	

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	3 ^[3]	4
Units: Months				
median (full range (min-max))	1.8 (1.8 to 1.8)	15.6 (15.6 to 15.6)	9999 (9999 to 9999)	18.4 (3.8 to 27.2)

Notes:

[3] - "9999" - Median DOR was not reached by the time of last disease assessment.

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1 ^[4]	5	0 ^[5]	
Units: Months				
median (full range (min-max))	9999 (9999 to 9999)	5.6 (2.8 to 16.1)	(to)	

Notes:

[4] - "9999" - Median DOR min./max. was not reached by the time of last disease assessment.

[5] - No DOR data was available for this participant.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Clinical Benefit by Immune-related Response Criteria (irRC)

End point title	Duration of Clinical Benefit by Immune-related Response Criteria (irRC)
-----------------	---

End point description:

Duration of clinical benefit was defined as the time interval between the date of the earliest qualifying confirmed/unconfirmed best response using irRC and the date of progressive disease (PD) or death for any cause, whichever occurred first. Duration of clinical benefit in months was calculated as: (date of PD or death – date of first confirmed/unconfirmed irCR/irPR or irSD + 1)/30.4375. Duration of clinical benefit included only participants with confirmed/unconfirmed response of irCR/irPR or irSD using irRC. Participants without progression, symptomatic deterioration, or death were censored at the date of the last tumor assessment. Median duration of clinical benefit and 95% CI were estimated using the Kaplan Meier method. The analysis population included all enrolled participants who received at least 1 injection of G100 after standard local radiation and had a confirmed/unconfirmed response of irCR/irPR or irSD using irRC.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 42 months

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	11	12
Units: Months				
median (full range (min-max))	2.5 (1.8 to 3.4)	20.8 (0.0 to 26.0)	6.9 (0.0 to 16.2)	9.2 (2.8 to 27.2)

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	13	0 ^[6]	
Units: Months				
median (full range (min-max))	7.2 (0.0 to 20.1)	4.3 (0.0 to 20.0)	(to)	

Notes:

[6] - No Duration of Clinical Benefit data was available for this participant.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free Survival (PFS) by Immune-related Response Criteria (irRC)

End point title	Progression-free Survival (PFS) by Immune-related Response Criteria (irRC)
-----------------	--

End point description:

PFS was defined as time from date of first study treatment to date of first disease progression (a $\geq 25\%$ increase in tumor burden from the lowest level recorded) by irRC criteria, symptomatic deterioration, or death due to any cause, whichever occurred first. Participants without progression, symptomatic deterioration, or death were censored at the date of the last tumor assessment. Progression-free survival in months is calculated as: (date of first progression, symptomatic deterioration, or death [any reason] – date of first dose +1)/30.4375. The irRC modification required a PD confirmation no less than 4 weeks from first documentation of PD. Summary of PFS including median, 95% CI was estimated using the Kaplan-Meier method. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 42 months

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	13	13
Units: Months				
median (full range (min-max))	4.9 (3.7 to 5.3)	22.6 (1.9 to 27.7)	7.4 (1.7 to 33.7)	11.1 (1.9 to 32.5)

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	14	1 ^[7]	
Units: Months				
median (full range (min-max))	9.8 (1.9 to 21.9)	7.7 (1.4 to 22.6)	9999 (9999 to 9999)	

Notes:

[7] - "9999" - median PFS was not reached (no disease progression or death).

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

Overall Survival (OS) was defined as the time from date of first study treatment to death due to any cause. Overall survival in months was calculated as: ([date of death – date of first dose] +1)/30.4375. Participants who were alive at the end of study were censored at the last date the participant was known to be alive or data analysis cutoff date, whichever was earlier. Summary of OS including median, 95% CI was estimated using the Kaplan-Meier method. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 42 months

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[8]	3 ^[9]	13 ^[10]	13 ^[11]
Units: Months				
median (full range (min-max))	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)

Notes:

[8] - "9999" - median OS was not reached (insufficient number of deaths).

[9] - "9999" - median OS was not reached (insufficient number of deaths).

[10] - "9999" - median OS was not reached (insufficient number of deaths).

[11] - "9999" - median OS was not reached (insufficient number of deaths).

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4 ^[12]	14 ^[13]	1 ^[14]	
Units: Months				
median (full range (min-max))	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	

Notes:

[12] - "9999" - median OS was not reached (insufficient number of deaths).

[13] - "9999" - median OS was not reached (insufficient number of deaths).

[14] - "9999" - median OS was not reached (insufficient number of deaths).

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Tumor Response Based on irRC Abscopal Sites

End point title	Overall Tumor Response Based on irRC Abscopal Sites
-----------------	---

End point description:

Abscopal tumor responses were assessed in non-treated, distal tumor sites. Immune-related Response Criteria irRC requires confirmatory restaging to determine if tumor size increase is due to true progression instead of immune inflammation and that new lesions add to tumor size calculations are not determinants of progressive disease. An immune-related Complete Response (irCR) is the disappearance of all lesions, and no new lesions; an immune-related Partial Response (irPR) is a $\geq 50\%$ drop in tumour burden from baseline; and immune related Progressive Disease (irPD) is a $\geq 25\%$ increase in tumour burden from the lowest level recorded. Everything else was considered immune-related Stable Disease (irSD). Tumor staging by CT or MRI was performed. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post baseline disease assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 42 months

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	13	13
Units: Participants				
Complete Response (irCR)	0	0	0	0
Partial Response (irPR)	0	1	4	3
Stable Disease (irSD)	1	2	4	8
Progressive Disease (irPD)	1	0	4	2

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	14	1	
Units: Participants				
Complete Response (irCR)	0	0	0	
Partial Response (irPR)	0	3	0	

Stable Disease (irSD)	3	9	1	
Progressive Disease (irPD)	1	2	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Response for Complete Response and Partial Response Participants

End point title	Time to Response for Complete Response and Partial Response Participants
End point description:	
Time to Response for CR and PR participants was defined as time from date of first study treatment to the date of CR or PR response first documented. Complete Response (irCR) is the disappearance of all lesions, and no new lesions; an immune-related Partial Response (irPR) is a $\geq 50\%$ drop in tumor burden from baseline. Time to response in months was calculated as: (date of first CR or PR minus date of first dose + 1)/30.4375. Summary of Time to Response including median and range was estimated using Kaplan-Meier method. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.	
End point type	Secondary
End point timeframe:	
Up to 42 months	

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	2	3	6
Units: Months				
median (full range (min-max))	1.9 (1.9 to 1.9)	1.9 (1.9 to 1.9)	2.3 (1.7 to 18.1)	4.1 (2.2 to 14.1)

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1	6	0 ^[15]	
Units: Months				
median (full range (min-max))	2.6 (2.6 to 2.6)	5.2 (1.9 to 7.3)	(to)	

Notes:

[15] - No Time to Response data was available for this participant.

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Next Treatment (TTNT)

End point title	Time to Next Treatment (TTNT)
-----------------	-------------------------------

End point description:

Time to next treatment was defined as the time from the date of first study treatment to the start date of subsequent therapy after PD. Immune-related Progressive Disease (irPD) is a $\geq 25\%$ increase in tumor burden from the lowest level recorded. Participants who did not receive subsequent therapy after PD were censored at the date of last contact or death. Summary of time to next treatment including median and range was estimated using the Kaplan-Meier method. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 42 months

End point values	Part 1: Local Radiation + G100 5µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	1 ^[16]	8	6 ^[17]
Units: Months				
median (full range (min-max))	5.4 (4.1 to 6.6)	9999 (9999 to 9999)	12.7 (1.9 to 33.7)	9999 (9999 to 9999)

Notes:

[16] - "9999" - median TTNT was not reached (insufficient number of treatments by time of last assessment).

[17] - "9999" - median was not reached (insufficient number of treatments by time of last assessment).

End point values	Part 2: Local Radiation, G100 20µg/lesion in Large Tumors	Part 3: Local Radiation + G100 20µg/lesion	Part 4: G100 20µg/lesion and Pembrolizumab 200mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1 ^[18]	6 ^[19]	0 ^[20]	
Units: Months				
median (full range (min-max))	9999 (9999 to 9999)	9999 (9999 to 9999)	(to)	

Notes:

[18] - "9999" - median TTNT was not reached (insufficient number of treatments by time of last assessment).

[19] - "9999" - median TTNT was not reached (insufficient number of treatments by time of last assessment).

[20] - This participant did not have irPD data.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to approximately 42 months

Adverse event reporting additional description:

The analysis population included all treated participants. Medical Dictionary for Regulatory Activities (MedDRA) terms "Neoplasm progression", "Malignant neoplasm progression" and "Disease progression" not related to study treatment were excluded as AEs as considered due to cancer progression. No participant was enrolled or dosed in Part 5.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

Reporting groups

Reporting group title	Part 2: Local Radiation + G100 10µg/lesion
-----------------------	--

Reporting group description:

Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.

Reporting group title	Part 1: Local Radiation + G100 10µg/lesion
-----------------------	--

Reporting group description:

Part 1 + Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.

Reporting group title	Part 1: Local Radiation + G100 5µg/lesion
-----------------------	---

Reporting group description:

Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.

Reporting group title	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg
-----------------------	--

Reporting group description:

Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.

Reporting group title	Part 2: Local Radiation, G100 20 µg/lesion in Large Tumors
-----------------------	--

Reporting group description:

Part 2: Local radiation and G100 at 20 µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks.

Reporting group title	Part 4: G100 20µg/lesion and pembrolizumab 200mg
-----------------------	--

Reporting group description:

Part 4: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.

Reporting group title	Part 3: Local Radiation + G100 20µg/lesion
-----------------------	--

Reporting group description:

Part 3: Local radiation and G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.

Serious adverse events	Part 2: Local Radiation + G100 10µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 1: Local Radiation + G100 5µg/lesion
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)

number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Multiple fractures			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Septic shock			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serious adverse events	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg	Part 2: Local Radiation, G100 20 µg/lesion in Large Tumors	Part 4: G100 20µg/lesion and pembrolizumab 200mg
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 13 (30.77%)	0 / 4 (0.00%)	0 / 1 (0.00%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			

Multiple fractures subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions Pyrexia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders Abdominal pain upper			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders Adrenal insufficiency			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations Septic shock			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 3: Local Radiation + G100 20µg/lesion		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 14 (0.00%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications Multiple fractures			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Septic shock			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part 2: Local Radiation + G100 10µg/lesion	Part 1: Local Radiation + G100 10µg/lesion	Part 1: Local Radiation + G100 5µg/lesion
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 13 (100.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Vascular disorders			
Diastolic hypertension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Embolism			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flushing			

subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Haematoma			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Hypotension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Systolic hypertension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Varicose vein			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Administration site pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			

subjects affected / exposed	0 / 13 (0.00%)	2 / 3 (66.67%)	1 / 3 (33.33%)
occurrences (all)	0	2	1
Feeling hot			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 13 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Infusion site swelling			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injection site bruising			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Injection site discomfort			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Injection site erythema			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	3 / 13 (23.08%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	5	0	0
Injection site reaction			
subjects affected / exposed	1 / 13 (7.69%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	5	1	0
Injection site swelling			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oedema peripheral			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Reproductive system and breast disorders Epididymal cyst subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Oedema genital subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Testicular atrophy subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Testis discomfort subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vulvovaginal inflammation subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Dyspnoea			

subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Nasal congestion			
subjects affected / exposed	2 / 13 (15.38%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Oropharyngeal pain			
subjects affected / exposed	4 / 13 (30.77%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	4	0	0
Pleural effusion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Productive cough			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pulmonary congestion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Throat irritation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Libido decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Restlessness			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 13 (7.69%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Blast cell count increased			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Blood bilirubin decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	2 / 13 (15.38%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Blood creatinine decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blood glucose increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			

subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Haemoglobin increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	2 / 13 (15.38%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	3	1	0
Neutrophil count decreased			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Platelet count decreased			
subjects affected / exposed	2 / 13 (15.38%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
White blood cell count decreased			
subjects affected / exposed	2 / 13 (15.38%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	4	1	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Expired product administered			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Radiation associated pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Radiation skin injury			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Skin laceration subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Cardiac disorders			
Coronary artery disease subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Myocardial fibrosis subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Nervous system disorders			
Carpal tunnel syndrome subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Dysgeusia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Neuropathy peripheral subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Nystagmus			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 2	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Blood loss anaemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Leukopenia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Lymph node pain subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Ear and labyrinth disorders			
Ear congestion subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Eye disorders			
Diplopia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Eyelid ptosis			

subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Abdominal distension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	2	0	1
Colitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dental caries			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	2 / 13 (15.38%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Dyspepsia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Flatulence			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hiatus hernia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia oral			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Inguinal hernia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Nausea			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Rectal tenesmus			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Toothache			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	2
Vomiting			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Ecchymosis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Erythema			

subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	2 / 13 (15.38%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Rash papular			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Skin discolouration			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin swelling			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin texture abnormal			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Hydronephrosis subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Urinary hesitation subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Bone pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Gouty arthritis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Groin pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Musculoskeletal chest pain			

subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Plantar fasciitis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Candida infection			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Cellulitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Helicobacter duodenitis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Herpes virus infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Nasopharyngitis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oesophagitis bacterial			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oral herpes			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinovirus infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	2 / 13 (15.38%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Tooth infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 13 (15.38%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	5	0	0
Urinary tract infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperlipidaemia			

subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypernatraemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg	Part 2: Local Radiation, G100 20 µg/lesion in Large Tumors	Part 4: G100 20µg/lesion and pembrolizumab 200mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 13 (100.00%)	4 / 4 (100.00%)	1 / 1 (100.00%)
Vascular disorders			
Diastolic hypertension			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Embolism			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Flushing			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Haematoma			

subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Hot flush			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Hypertension			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	4	0	0
Hypotension			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Systolic hypertension			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Varicose vein			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Administration site pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Asthenia			
subjects affected / exposed	4 / 13 (30.77%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	7	0	0
Chest pain			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Chills			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	4 / 13 (30.77%)	2 / 4 (50.00%)	1 / 1 (100.00%)
occurrences (all)	4	2	1
Feeling hot			

subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Infusion site swelling			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Injection site bruising			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Injection site discomfort			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Injection site erythema			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Injection site reaction			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	4	0	0
Injection site swelling			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Pyrexia			

subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 4 (25.00%) 4	0 / 1 (0.00%) 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Seasonal allergy			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Epididymal cyst			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Oedema genital			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Testicular atrophy			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Testis discomfort			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Vulvovaginal inflammation			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	4 / 13 (30.77%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	5	0	0
Dyspnoea			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			

subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	1 / 1 (100.00%)
occurrences (all)	4	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Pulmonary congestion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Sinus congestion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Throat irritation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 13 (7.69%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
Insomnia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Libido decreased			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Restlessness			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Sleep disorder subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	3 / 13 (23.08%) 5	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Blast cell count increased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 5	1 / 4 (25.00%) 2	0 / 1 (0.00%) 0
Blood bilirubin decreased subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Blood creatinine decreased subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Breath sounds abnormal subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Haemoglobin increased			

subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Neutrophil count decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0
Expired product administered			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0
Fall			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Procedural pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Radiation associated pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Radiation skin injury			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Skin laceration			

subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Cardiac disorders			
Coronary artery disease subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Myocardial fibrosis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Nervous system disorders			
Carpal tunnel syndrome subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 3	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Dysgeusia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Nystagmus subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Presyncope			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 13 (15.38%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	3	4	0
Blood loss anaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Leukocytosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Lymph node pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			

subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Abdominal pain			
subjects affected / exposed	2 / 13 (15.38%)	2 / 4 (50.00%)	0 / 1 (0.00%)
occurrences (all)	4	3	0
Colitis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Constipation			
subjects affected / exposed	2 / 13 (15.38%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	2	2	0
Dental caries			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	4 / 13 (30.77%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	4	0	0
Dyspepsia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Dysphagia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0

Hiatus hernia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	6 / 13 (46.15%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	7	2	0
Rectal tenesmus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	3 / 13 (23.08%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Ecchymosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Hyperhidrosis			

subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	1 / 13 (7.69%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
Rash			
subjects affected / exposed	3 / 13 (23.08%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	5	0	0
Rash papular			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin swelling			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin texture abnormal			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Urinary hesitation subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 2	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	3 / 13 (23.08%) 3	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Bone pain subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Gouty arthritis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0
Groin pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Musculoskeletal pain			

subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Myalgia			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Pain in extremity			
subjects affected / exposed	1 / 13 (7.69%)	2 / 4 (50.00%)	0 / 1 (0.00%)
occurrences (all)	2	2	0
Plantar fasciitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Candida infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Diverticulitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Helicobacter duodenitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Herpes virus infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0

Oesophagitis bacterial subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Oral herpes subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Rhinovirus infection subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	3 / 13 (23.08%) 5	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 4 (25.00%) 7	0 / 1 (0.00%) 0
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0
Hypernatraemia			

subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Hypocalcaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Hyponatraemia			
subjects affected / exposed	2 / 13 (15.38%)	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0

Non-serious adverse events	Part 3: Local Radiation + G100 20µg/lesion		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	14 / 14 (100.00%)		
Vascular disorders			
Diastolic hypertension			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Embolism			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Flushing			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Haematoma			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hot flush			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Hypotension			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Systolic hypertension			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Varicose vein			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
General disorders and administration site conditions			
Administration site pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Asthenia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Chest pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Fatigue			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Feeling hot			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Influenza like illness			

subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Infusion site swelling			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Injection site bruising			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Injection site discomfort			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Injection site erythema			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Injection site pain			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Injection site reaction			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	8		
Injection site swelling			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Peripheral swelling			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Immune system disorders			

Drug hypersensitivity subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Reproductive system and breast disorders			
Epididymal cyst subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Oedema genital subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Testicular atrophy subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Testis discomfort subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Vulvovaginal inflammation subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders			
Asthma subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Cough subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Dyspnoea subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Nasal congestion subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Oropharyngeal pain			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pleural effusion			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pulmonary congestion			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Sinus congestion			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Throat irritation			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Upper-airway cough syndrome			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Libido decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Restlessness			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Sleep disorder			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blast cell count increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood bilirubin decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Blood creatinine decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Blood glucose increased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Breath sounds abnormal			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Haemoglobin increased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Lymphocyte count decreased			

subjects affected / exposed occurrences (all)	3 / 14 (21.43%) 6		
Neutrophil count decreased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2		
Platelet count decreased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
White blood cell count decreased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Expired product administered subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Fall subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Procedural pain subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Radiation associated pain subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Radiation skin injury subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Skin laceration subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Cardiac disorders			

Coronary artery disease subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Myocardial fibrosis subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Sinus bradycardia subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Tachycardia subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Nervous system disorders			
Carpal tunnel syndrome subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Dizziness subjects affected / exposed occurrences (all)	2 / 14 (14.29%) 3		
Dysgeusia subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Headache subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Nystagmus subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Presyncope subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood loss anaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Leukocytosis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Leukopenia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Lymph node pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Tinnitus			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Vertigo			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Eye disorders			
Diplopia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Eyelid ptosis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Periorbital oedema			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Vision blurred			

subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Abdominal pain			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Colitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Dental caries			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Dyspepsia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dysphagia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Hiatus hernia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Hypoaesthesia oral subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Inguinal hernia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Nausea subjects affected / exposed occurrences (all)	3 / 14 (21.43%) 4		
Rectal tenesmus subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Toothache subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Vomiting subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Dry skin subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Ecchymosis subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Erythema subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Hyperhidrosis subjects affected / exposed occurrences (all)	2 / 14 (14.29%) 4		
Night sweats			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Rash papular			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Skin discolouration			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Skin hyperpigmentation			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Skin reaction			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Skin swelling			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Skin texture abnormal			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hydronephrosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Urinary hesitation			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypothyroidism			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Back pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Bone pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Flank pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Gouty arthritis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Groin pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Musculoskeletal chest pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Myalgia			

subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Pain in extremity			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Plantar fasciitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Candida infection			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Diverticulitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Helicobacter duodenitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Herpes virus infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Influenza			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Oesophagitis bacterial			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Oral herpes			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Rhinovirus infection			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Sinusitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Tooth infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Hyperkalaemia			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Hyperlipidaemia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Hypernatraemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hyperuricaemia			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hyponatraemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 November 2015	AM1 - This amendment added a treatment arm to Part 2 Patient Expansion to examine the sequential addition of anti-PD1 antibody pembrolizumab to intratumoral G100.
05 January 2017	AM3 - Added Part 3 G100 20µg Dose Expansion arm to allow for up to 25 participants at the 20µg dose using the same tumor size entrance criteria as the other non-Large Tumor arms.
31 July 2018	AM4 - Added Part 4, a new dose escalation and expansion arm to examine G100 20µg in combination with pembrolizumab in relapsed or refractory follicular lymphoma without radiation therapy in single and multiple tumor lesions. Added Part 5, a new dose escalation and expansion to examine the safety and preliminary clinical efficacy of G100 in combination with rituximab in follicular lymphoma.
31 August 2018	AM4A - Revised the Inclusion criteria for Part 4 to only include participants with relapsed or refractory disease after ≥3 prior therapies. Part 5 was revised to limit the intratumoral G100 treatment to a single tumor mass during Patient Expansion.
15 November 2018	AM4B - An exploratory objective of evaluating Pharmacokinetics and Pharmacodynamic properties of G100 and appropriate sample collection were added. Dose limiting toxicity criteria for Parts 4 and 5 were added.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
11 June 2019	The trial was terminated (Halted Prematurely) for business reasons.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Part 5, G100 plus Rituximab, Dose Escalation: 12 to 24 participants were planned; no participant was enrolled or dosed. The trial was terminated (Halted Prematurely) for business reasons.

Notes: